What we still don’t know about weight-loss drugs

Weight-loss drugs like Mounjaro and Zepbound are generating significant revenue for Eli Lilly, but questions remain about their effects on brain health, pregnancy, and long-term use. While these drugs show promise in treating obesity and diabetes, they may not benefit individuals with Alzheimer's disease and can lead to weight gain during pregnancy when discontinued. Concerns also arise regarding the safety and efficacy of GLP-1 agonist drugs before, during, and after pregnancy, as well as the potential long-term consequences for healthy-weight individuals using them for weight loss. Further research is needed to address these uncertainties and determine the appropriate usage of these medications.